Newsroom
Strive to Deliver Breakthroughs
-
March 12, 2020
Harbour BioMed Raises $75 Million Series B+ Venture Capital Financing To Accelerate Its Innovative Pipeline
New funding drives advancement of next generation biologic therapeutics pipeline Cambridge, MA; Rotterdam, The Netherlands & Suzhou, CN &...
View more -
March 06, 2020
Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19
Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai&...
View more -
February 28, 2020
Harbour BioMed Receives U.S. FDA IND Approval for Phase 2 Clinical Trial and Orphan Drug Designation for Anti-PD-L1 Monoclonal Antibody, HBM9167
Cambridge, MA; Rotterdam, NL; Suzhou, CN February 27, 2020 Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval o...
View more -
February 28, 2020
Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer
First fully human, heavy chain only antibody in human trials has shown potent activity in preclinical studies through differentiated mechanism of action &nb...
View more -
February 21, 2020
Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody
Cambridge, MA, Rotterdam, NL, Suzhou, CN – February 21, 2020 Harbour BioMed (HBM) today announced completion of a Phase 1 study of HBM...
View more -
November 04, 2019
Harbour BioMed Announces Initiation of First-in-Human Study of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors
HBM4003 is the First Fully Human Heavy Chain Only Antibody Ever to Enter Human Trials Cambridge, MA, Rotterdam, NL, Shanghai, CN (November...
View more -
October 11, 2019
Harbour BioMed Announces Completion of Phase 2 Study of HBM9036 in Patients with Moderate-to-Severe Dry Eye Disease in China
Successful completion of Phase 2 monotherapy trial paves way for Phase 3 trials in China in early 2020 Cambridge, MA, Rotterdam, NL, Shanghai...
View more -
July 10, 2019
Yinuoke and Harbour BioMed Announce A Strategic Alliance to Develop Innovative Biologics to Address Unmet Patients' Needs
Global collaboration focusing on novel biologics in Oncology Cambridge, MA, Rotterdam, NL, Shanghai, CN July 10, 2019 Yinouke an...
View more -
June 19, 2019
Harbour BioMed Appoints Immunology Research Leader Kenneth M. Murphy, MD, PhD to its Scientific Advisory Board
CAMBRIDGE, MA, ROTTERDAM, The Netherlands and Shanghai, China, June 19, 2019 – Harbour BioMed (“HBM”) announced today the appointment of Kenn...
View more -
June 13, 2019
Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development
Rotterdam, The Netherlands, Cambridge, MA, and Shanghai, China June 13th, 2019 Harbour BioMed (HBM) and Erasmus MC, University Med...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1